Dactinomycin in acute myeloid leukemia with NPM1 mutations.
Guillaume BeziatSuzanne TavitianSarah BertoliFrançoise HuguetLaetitia LargeaudIsabelle LuquetFrançois VergezJean Baptiste RieuPierre BoriesEric DelabesseChristian RecherPublished in: European journal of haematology (2020)
Dactinomycin is an inexpensive and easily available drug that may induce significant responses in few AML patients with NPM1 mutations with an acceptable safety profile.